Lilly completes acquisition of CoLucid Pharmaceuticals

Acquisition enhances Lilly's existing pain management.

As of the expiration of the tender offer, 17,410,607 shares of CoLucid common stock were validly tendered, representing approximately 90.3% of the shares outstanding, and have been accepted for payment under the terms of the tender offer. Following its acceptance of the tendered shares, Lilly completed the acquisition of CoLucid through a second-step merger.

"We are pleased to announce the completion of our acquisition of CoLucid, which will enhance Lilly's existing pain management portfolio and add a potential near-term launch to our late-stage pipeline," said David R. Ricks, president and CEO. "More than 36 million people suffer from migraine in the US alone, and lasmiditan could represent the first significant innovation for the acute treatment of migraine in more than 20 years."

The impact of the acquisition, including the expected acquired in-process research and development charge of approximately $850 million (no tax benefit), or approximately $0.80 per share, will be reflected beginning in Lilly's first-quarter 2017 financial statements. The company's 2017 earnings per share guidance on a reported basis is reduced by the estimated amount of the charge, or $0.80 per share, as previously stated in the company's fourth-quarter earnings announcement in January of this year. There is no change to the company's 2017 non-GAAP earnings per share guidance as a result of this transaction.